A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
N/A
Prostate cancer is the most common non-skin cancer among men in the United ...
Status
Recruiting
Location
Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
PHASE1
The purpose of this substudy is to assess the efficacy and safety of ifinat...
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
N/A
The aim of this study is to assess treatment patterns, characteristics, and...
Status
Recruiting
Location
Novartis
Start Date
2026-06-30
Trial ID
NCT07677267
Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
N/A
This prospective observational study will evaluate quality of life, functio...